Shares of Silverback Therapeutics, Inc. (NASDAQ:SBTX – Get Free Report) dropped 6% during trading on Friday . The stock traded as low as $8.3250 and last traded at $8.41. Approximately 2,496,912 shares were traded during mid-day trading, an increase of 639% from the average daily volume of 337,931 shares. The stock had previously closed at $8.9450.
Silverback Therapeutics Stock Performance
The firm’s fifty day simple moving average is $9.78 and its 200-day simple moving average is $13.42. The stock has a market cap of $303.25 million, a P/E ratio of -3.48 and a beta of 0.60.
About Silverback Therapeutics
Silverback Therapeutics, Inc, a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver.
Featured Stories
- Five stocks we like better than Silverback Therapeutics
- Expert Stock Trading Psychology Tips
- Are These 3 Oversold Tech Giants Ready to Rebound?
- 3 Warren Buffett Stocks to Buy Now
- If You Wait for the Dip, Micron Technology Could Leave You Behind
- Pros And Cons Of Monthly Dividend Stocks
- 3 Stocks Quietly Powering the AI and Tech Revolution
Receive News & Ratings for Silverback Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silverback Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
